NRSG 1320 FINAL REVIEW - OB/GYN
EXAM 2025 QUESTIONS AND ANSWERS
Teratogens - Medications - ANS Ace Inhibitors, Carbamazepines (anticonvulsant), Cocaine,
Warfarin (Coumadin)
When is the fetus more vulnerable to teratogen exposure? - ANS 2-8 weeks; during
organogenesis
FDA 5 categories of safety - ANS A, B, C, D or X
A - least risk
X- most risk
IPV - Intimate partner violence - ANS Screening test done at each prenatal visit; ask the
patient if they feel safe
associated with poor outcomes for pregnancy
S/S of IPV - ANS Repeated non-specific complains, overuse of the healthcare system,
hesitancy, embarrassment, or evasiveness r/t history of injuries
BPP (Biophysical profile) - ANS "fetal physical examination"/ US and NST
Screening test done by ultrasound to determine fetal well-being; each category is assigned a
score of 2, 1 or 0 (8-10 is normal)
6, should be reassessed in 24 hours
COPYRIGHT © 2025 FYNDLAY ALL RIGHTS RESERVED 1
, <4, delivery should occur without delay
NST (non-stress test) - ANS Assess fetal well being by using ultrasound for fetal HR and a toco
on the fundus of the uterus to monitor contractions
Reactive NST - ANS Accelerations fo the FHR with fetal movement felt by the mother ensures
adequate oxygenation and intact CNS
Non-reactive NST - ANS No accelerations of FHR; may require acoustic stimulation
Additional testing required
preeclampsia - ANS Hypertension accompanied by proteinuria after the 20th week of
gestation
Decreased placental perfusion and placental hypoxia
s/s of preeclampsia - ANS Blood pressure > 140/90
Visual problems (seeing spots/blurred vision)
Edema (puffy face)
Epigastric pain
Low platelets
Proteinuria
Elevated AST/ALT (liver enzymes)
HELLP - ANS Serious complication of preeclampsia
Hemolysis, elevated liver enzymes, low platelets < 100,000
Right upper gastric pain, general malaise, nausea
Petechiae and bleeding from injection and IV sites
COPYRIGHT © 2025 FYNDLAY ALL RIGHTS RESERVED 2
EXAM 2025 QUESTIONS AND ANSWERS
Teratogens - Medications - ANS Ace Inhibitors, Carbamazepines (anticonvulsant), Cocaine,
Warfarin (Coumadin)
When is the fetus more vulnerable to teratogen exposure? - ANS 2-8 weeks; during
organogenesis
FDA 5 categories of safety - ANS A, B, C, D or X
A - least risk
X- most risk
IPV - Intimate partner violence - ANS Screening test done at each prenatal visit; ask the
patient if they feel safe
associated with poor outcomes for pregnancy
S/S of IPV - ANS Repeated non-specific complains, overuse of the healthcare system,
hesitancy, embarrassment, or evasiveness r/t history of injuries
BPP (Biophysical profile) - ANS "fetal physical examination"/ US and NST
Screening test done by ultrasound to determine fetal well-being; each category is assigned a
score of 2, 1 or 0 (8-10 is normal)
6, should be reassessed in 24 hours
COPYRIGHT © 2025 FYNDLAY ALL RIGHTS RESERVED 1
, <4, delivery should occur without delay
NST (non-stress test) - ANS Assess fetal well being by using ultrasound for fetal HR and a toco
on the fundus of the uterus to monitor contractions
Reactive NST - ANS Accelerations fo the FHR with fetal movement felt by the mother ensures
adequate oxygenation and intact CNS
Non-reactive NST - ANS No accelerations of FHR; may require acoustic stimulation
Additional testing required
preeclampsia - ANS Hypertension accompanied by proteinuria after the 20th week of
gestation
Decreased placental perfusion and placental hypoxia
s/s of preeclampsia - ANS Blood pressure > 140/90
Visual problems (seeing spots/blurred vision)
Edema (puffy face)
Epigastric pain
Low platelets
Proteinuria
Elevated AST/ALT (liver enzymes)
HELLP - ANS Serious complication of preeclampsia
Hemolysis, elevated liver enzymes, low platelets < 100,000
Right upper gastric pain, general malaise, nausea
Petechiae and bleeding from injection and IV sites
COPYRIGHT © 2025 FYNDLAY ALL RIGHTS RESERVED 2
